由于收购方库瓦未能按时筹集收购资金，利萨塔股价暴跌

路透中文

Jul 21

BUZZ-由于收购方库瓦未能按时筹集收购资金，利萨塔股价暴跌

7月21日 - ** 药物研发公司 Lisata Therapeutics（LSTA.O）股价下跌 30.8%，至 2.44 美元，创近六个月新低

** 利萨塔表示，寻求收购其公司的库瓦实验室（Kuva Labs）在告知该公司无法获得足够融资后，尚未支付收购要约中提交的股份款项——美国证券交易委员会（SEC）文件显示 (link)

** Kuva 于 1 月 (link) 同意收购 Lisata，尽管具体的现金加认股权 (link) 交易结构经过多次修订，且要约收购截止日期也多次延长

** 作为Kuva Labs旗下子公司，Kuva Acquisition Corp发起的要约收购已于7月20日晚间到期

** 约610万股（约占Lisata已发行股份总数的66.8%）已被接受且未被撤回，满足了最低接受条件

** Lisata表示要约的所有条件均已满足，但Kuva表示无法及时筹集到足够的资金

** Kuva尚未接受或支付相关股份款项，Lisata表示目前正在权衡法律选项

** 截至上一交易日收盘，该股年内累计涨幅达89%

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2653203349"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653203349\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653203349?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-07-21 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653203349","market":"us","top_or_hot":-1,"title":"由于收购方库瓦未能按时筹集收购资金，利萨塔股价暴跌","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-由于收购方库瓦未能按时筹集收购资金，利萨塔股价暴跌</title></head><body><p>\n<span>7月21日</span><span> - </span>** 药物研发公司 <a href=\"https://laohu8.com/S/LSTA\">Lisata Therapeutics</a>（<span>LSTA.O</span>）股价下跌 30.8%，至 2.44 美元，创近六个月新低</p><p>** 利萨塔表示，寻求收购其公司的库瓦实验室（Kuva Labs）在告知该公司无法获得足够融资后，尚未支付收购要约中提交的股份款项——美国证券交易委员会（SEC）文件显示 (link)</p><p>** Kuva 于 1 月 (<span>link</span>) 同意收购 Lisata，尽管具体的现金加认股权 (<span>link</span>) 交易结构经过多次修订，且要约收购截止日期也多次延长</p><p>** 作为Kuva Labs旗下子公司，Kuva Acquisition Corp发起的要约收购已于7月20日晚间到期</p><p>** 约610万股（约占Lisata已发行股份总数的66.8%）已被接受且未被撤回，满足了最低接受条件</p><p>** Lisata表示要约的所有条件均已满足，但Kuva表示无法及时筹集到足够的资金</p><p>** Kuva尚未接受或支付相关股份款项，Lisata表示目前正在权衡法律选项 </p><p>** 截至上一交易日收盘，该股年内累计涨幅达89% </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>由于收购方库瓦未能按时筹集收购资金，利萨塔股价暴跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n由于收购方库瓦未能按时筹集收购资金，利萨塔股价暴跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-07-21 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-由于收购方库瓦未能按时筹集收购资金，利萨塔股价暴跌</title></head><body><p>\n<span>7月21日</span><span> - </span>** 药物研发公司 <a href=\"https://laohu8.com/S/LSTA\">Lisata Therapeutics</a>（<span>LSTA.O</span>）股价下跌 30.8%，至 2.44 美元，创近六个月新低</p><p>** 利萨塔表示，寻求收购其公司的库瓦实验室（Kuva Labs）在告知该公司无法获得足够融资后，尚未支付收购要约中提交的股份款项——美国证券交易委员会（SEC）文件显示 (link)</p><p>** Kuva 于 1 月 (<span>link</span>) 同意收购 Lisata，尽管具体的现金加认股权 (<span>link</span>) 交易结构经过多次修订，且要约收购截止日期也多次延长</p><p>** 作为Kuva Labs旗下子公司，Kuva Acquisition Corp发起的要约收购已于7月20日晚间到期</p><p>** 约610万股（约占Lisata已发行股份总数的66.8%）已被接受且未被撤回，满足了最低接受条件</p><p>** Lisata表示要约的所有条件均已满足，但Kuva表示无法及时筹集到足够的资金</p><p>** Kuva尚未接受或支付相关股份款项，Lisata表示目前正在权衡法律选项 </p><p>** 截至上一交易日收盘，该股年内累计涨幅达89% </p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nL4T43N198:1","article_id":"2653203349","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653203349","pubTimestamp":1784641331,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-由于收购方库瓦未能按时筹集收购资金，利萨塔股价暴跌7月21日-** 药物研发公司 Lisata Therapeutics（LSTA.O）股价下跌 30.8%，至 2.44 美元，创近六个月新低** 利萨塔表示，寻求收购其公司的库瓦实验室（Kuva Labs）在告知该公司无法获得足够融资后，尚未支付收购要约中提交的股份款项——美国证券交易委员会（SEC）文件显示 (link)** Kuva","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","LSTA":"LISATA THERAPEUTICS INC"},"translate_title":"Lisata shares plunge as acquirer Couva fails to raise money for the takeover on time","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LSTA":0.9},"content_text":"BUZZ-由于收购方库瓦未能按时筹集收购资金，利萨塔股价暴跌\n7月21日 - ** 药物研发公司 Lisata Therapeutics（LSTA.O）股价下跌 30.8%，至 2.44 美元，创近六个月新低** 利萨塔表示，寻求收购其公司的库瓦实验室（Kuva Labs）在告知该公司无法获得足够融资后，尚未支付收购要约中提交的股份款项——美国证券交易委员会（SEC）文件显示 (link)** Kuva 于 1 月 (link) 同意收购 Lisata，尽管具体的现金加认股权 (link) 交易结构经过多次修订，且要约收购截止日期也多次延长** 作为Kuva Labs旗下子公司，Kuva Acquisition Corp发起的要约收购已于7月20日晚间到期** 约610万股（约占Lisata已发行股份总数的66.8%）已被接受且未被撤回，满足了最低接受条件** Lisata表示要约的所有条件均已满足，但Kuva表示无法及时筹集到足够的资金** Kuva尚未接受或支付相关股份款项，Lisata表示目前正在权衡法律选项 ** 截至上一交易日收盘，该股年内累计涨幅达89%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}